Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medivir AB Announces Results from COSMOS study with Simeprevir and Sofosbuvir in Cirrhotic and Non-Cirrhotic HCV Genotype 1 Patients


Monday, 4 Nov 2013 04:30pm EST 

Medivir AB announced that data from the interferon-free COSMOS study demonstrates safety and efficacy of the investigational protease inhibitor simeprevir (TMC435) in combination with the investigational nucleotide inhibitor sofosbuvir (GS-7977), with and without ribavirin, in genotype 1 chronic hepatitis C adult patients with compensated liver disease. COSMOS is a phase IIa, randomized, open-label study investigating the safety and efficacy of simeprevir in combination with sofosbuvir, with and without ribavirin, for either 12 or 24 weeks. The study enrolled HCV genotype 1 patients who were prior null responders to treatment with interferon and ribavirin with METAVIR F0-F2 scores (cohort 1, n=80), or treatment-naive patients and prior null responders with METAVIR F3-F4 scores (cohort 2, n=87). 

Company Quote

76.25
-2.25 -2.87%
27 Mar 2015